The European Medicines Agency (EMA) and European Commission have published new educational materials on biosimilar medicines. The information, which is available in several European languages, is part of a collaboration to help patients and practitioners understand biosimilar medicines and explain how the EMA ensures they have the same safety and efficacy as their reference biological medicines.
‘A biosimilar is biological medicine that is highly similar in all essential aspects to a ‘reference’ biological medicine already authorised.’
The EMA have also published translations of the biosimilar guide for healthcare professionals which provides comprehensive information on the use of biosimilars and their regulation.
To read more please click here.
For more information on biosimilars, please see our section on MAP Online.